The Technical Analyst
CM Life Sciences, Inc. [CMLF]
Exchange: NASDAQ Sector: Financial Services Industry: Shell Companies
CM Life Sciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-7.05% $11.60
America/New_York / 23 jul 2021 @ 00:00
| RATING 2022-02-09 |
|---|
| S |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | |||
|---|---|---|---|
| 3/20 | 4/20 | 2/21 | |
| Revenue | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a |
| Ebit | n/a | n/a | |
| Asset | n/a | ||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1 288.89 | sector: PE -18.15 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1 288.89 | industry: PE -25.74 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 10.66 - 12.54 ( +/- 8.13%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-07-22 | Casdin Eli | Buy | 10 993 750 | Class A Common Stock |
| 2021-07-22 | Casdin Eli | Buy | 6 736 669 | Warrants to purchase Class A Common Stock (right to buy) |
| 2021-07-22 | Casdin Eli | Buy | 5 000 000 | Class A Common Stock |
| 2021-07-22 | Casdin Eli | Sell | 10 993 750 | Class B Common Stock |
| 2020-09-01 | George Sean E | Buy | 0 |
| INSIDER POWER |
|---|
| 0.00 |
| Last 6 transactions |
| Buy: 22 730 419 | Sell: 21 006 250 |
Forecast:
01:40 - $11.26
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $11.60 (-7.05% ) |
| Volume | 0.489 mill |
| Avg. Vol. | 0.723 mill |
| % of Avg. Vol | 67.64 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CMLF
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CMLF
CM Life Sciences, Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.
Latest Press Releases
2021-07-02 12:15:00 - Press Release
Cm Life Sciences And Sema4 Announce Release Of Definitive Proxy Statement For July 21 Shareholder Meeting To Vote On Business Combination
New york--(business wire)--cm life sciences (nasdaq: cmlf), a special purpose acquisition company, or spac, sponsored by affiliates of casdin capital, llc and corvex management lp, has filed its definitive proxy statement with the securities and exchange commission (the “sec”) in connection with the previously announced proposed business combination with sema4. the definitive proxy statement contains important information about the proposed business combination contemplated by the agreement and
2021-06-10 17:12:00 - Press Release
Sema4 And Cm Life Sciences Announce The Filing Of Amended Preliminary Proxy Statement
Stamford, conn.--(business wire)---- $cmlf #ai--the filing of the amended proxy statement marks the next step in the formal securities and exchange commission (sec) review process.
2021-05-06 17:31:00 - Press Release
Sema4 And Cm Life Sciences Announce The Filing Of The Schedule-14a Proxy Statement In Connection With The Proposed Merger
Stamford, conn.--(business wire)---- $cmlf #ai--sema4, a patient-centered health intelligence company leveraging ai and machine learning to derive data-driven insights, and cm life sciences (nasdaq: cmlf), a special purpose acquisition company, or spac, sponsored by affiliates of casdin capital, llc and corvex management lp, today announced the filing of the preliminary proxy statement related to their proposed business combination. the filing of the preliminary proxy statement initiates the formal securitie
2021-05-05 06:10:00 - Press Release
Cm Life Sciences Announces Filing Of Amended Annual Report On Form 10-k Relating To Restatement Of Financial Statements In Accordance With Recent Sec Guidance
New york--(business wire)--cm life sciences, inc. (nasdaq:cmlf) today announced that it has filed with the securities and exchange commission (sec) an amended annual report on form 10-k/a and a form 8-k reporting the restatement of certain of its previously issued financial statements. the restatement was following a statement issued on april 12, 2021 by the acting director of the division of corporation finance and the acting chief accountant of the sec relating to reporting considerations for
2021-02-12 21:00:00 - Press Release
Shareholder Alert: Monteverde & Associates Pc Announces An Investigation Of Cm Life Sciences, Inc. - Cmlf
New york, feb. 12, 2021 /prnewswire/ -- juan monteverde, founder and managing partner at monteverde & associates pc, a national securities firm rated top 50 in the 2018 and 2019 iss securities class action services report and headquartered at the empire state building in new york city, is...
Latest News
2021-07-02 12:15:00 - Business Wire
CM Life Sciences and Sema4 Announce Release of Definitive Proxy Statement for July 21 Shareholder Meeting to Vote on Business Combination
NEW YORK--(BUSINESS WIRE)--CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, has filed its definitive proxy statement with the Securities and Exchange Commission (the “SEC”) in connection with the previously announced proposed business combination with Sema4. The definitive proxy statement contains important information about the proposed business combination contemplated by the Agreement and
2021-06-12 12:10:00 - The Dog of Wall Street
3 Stocks Cathie Wood Keeps Buying
After every trading session, Ark Invest's Cathie Wood shows which stocks she has bought and sold throughout the day.
2021-06-10 17:12:00 - Business Wire
Sema4 and CM Life Sciences Announce the Filing of Amended Preliminary Proxy Statement
STAMFORD, Conn.--(BUSINESS WIRE)---- $CMLF #AI--The filing of the amended proxy statement marks the next step in the formal Securities and Exchange Commission (SEC) review process.
2021-05-27 09:55:06 - 24/7 Wall Street
Cathie Wood's ARK Invest Buys Over 330,000 Shares of CM Life Sciences
One of ARK Invest exchange-traded funds run by ETF star Cathie Wood bought over 330,000 shares of CM Life Sciences Inc.
2021-05-06 17:31:00 - Business Wire
Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed Merger
STAMFORD, Conn.--(BUSINESS WIRE)---- $CMLF #AI--Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, and CM Life Sciences (Nasdaq: CMLF), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced the filing of the preliminary proxy statement related to their proposed business combination. The filing of the preliminary proxy statement initiates the formal Securitie
2021-05-05 06:10:00 - Business Wire
CM Life Sciences Announces Filing of Amended Annual Report on Form 10-K Relating to Restatement of Financial Statements in Accordance with Recent SEC Guidance
NEW YORK--(BUSINESS WIRE)--CM Life Sciences, Inc. (NASDAQ:CMLF) today announced that it has filed with the Securities and Exchange Commission (SEC) an amended annual report on Form 10-K/A and a Form 8-K reporting the restatement of certain of its previously issued financial statements. The restatement was following a statement issued on April 12, 2021 by the Acting Director of the Division of Corporation Finance and the Acting Chief Accountant of the SEC relating to reporting considerations for
2021-04-01 03:59:28 - Seeking Alpha
CM Life Sciences II: SomaLogic Is Great, But Post-Merger SPAC Dilution Should Frighten Investors
CM Life Sciences II, Inc. is the second life-sciences-focused special purpose acquisition company from the Casdin-Meisters team launched in Feb 2021.
2021-02-23 14:12:57 - Seeking Alpha
CM Life Sciences: SPAC Acquires Sema4, A Promising AI Health Intelligence Co.
CM Life Sciences, Inc. is a life-sciences-focused special purpose acquisition company founded in July 2020 aiming to deploy $443M in raised cash to acquire a private company. CM LS selected their target, Sema4, a revenue-producing ('20: $190M|38% CAGR) health intelligence company with ~1K employees aiming to advance healthcare via a suite of next-gen diagnostics utilizing data-driven platform-insights.
2021-02-12 21:00:00 - PRNewsWire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of CM Life Sciences, Inc. - CMLF
NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...
2021-02-12 13:21:35 - Pulse2
CMLF Stock Price Increases Over 80% Over The Past Week: Why It Happened
The stock price of CM Life Sciences Inc (NASDAQ: CMLF) is trading up over 80% over the past week. This is why it happened.